StockNews.AI
PTN
StockNews.AI
187 days

Palatin Reports Second Quarter Fiscal Year 2025 Financial Results and Provides Business Update

1. Palatin Technologies completed database lock for Phase 2 obesity study, data due soon. 2. Upcoming topline data readout for PL8177 in ulcerative colitis expected this quarter.

3m saved
Insight
Article

FAQ

Why Bullish?

Positive data announcements can drive investor sentiment, as seen in successful clinical trials boosting similar biopharma stocks.

How important is it?

The article discusses pivotal clinical trial progress, directly impacting investor confidence and PTN's market performance.

Why Short Term?

The upcoming data releases may influence PTN's stock price in the near future, similar to past trial results affecting stock performance rapidly.

Related Companies

PTNTLISZIOP
Phase 2 obesity co-administration study with MC4R agonist bremelanotide plus GLP-1/GIP dual agonist tirzepatide Database lock completed Topline data readout expected later this month Novel 'next generation' selective MC4R long-acting peptide and an oral small molecule Multiple clinical trials targeted in calendar year 2025 For the treatment of general obesity, weight loss management, and rare MC4R pathway diseases, including hypothalamic obesity Phase 2 clinical study of PL8177 oral formulation for the treatment of ulcerative colitis Topline data readout expected later this quarter Teleconference and Webcast to be held on February 13, 2025, at 11:00 AM ET CRANBURY, N.J. , Feb. 13, 2025 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced financial results for its fiscal second quarter ended December 31, 2024 and the completion of database lock for its Phase 2 obesity co-administration study with melanocortin 4 receptor (MC4R) agonist bremelanotide plus glucagon like peptide-1/gastric inhibitory polypeptide (GLP-1/GIP) dual agonist tirzepatide.

Related News